ERBB2 and breast carcinoma: We conducted a descriptive study to clarify the actual patterns of perioperative chemotherapy regimens including anthracycline, taxane, or both in T ≥ 2, N+ , high-risk, early-stage, breast cancer patients not receiving anti-HER2 therapy.